

Stephen Lockhart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2780288/publications.pdf>

Version: 2024-02-01

30
papers

20,695
citations

430754

18
h-index

477173

29
g-index

34
all docs

34
docs citations

34
times ranked

27867
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	13.9	431
2	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.	13.9	215
3	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. <i>Vaccine</i> , 2022, 40, 1483-1492.	1.7	32
4	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
5	A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India. <i>Vaccine</i> , 2021, 39, 5313-5317.	1.7	0
6	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	13.9	346
7	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
8	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. <i>Nature Communications</i> , 2021, 12, 7105.	5.8	22
9	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
10	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
11	Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project. <i>Vaccine</i> , 2020, 38, 5896-5904.	1.7	20
12	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
13	Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. <i>Vaccine</i> , 2018, 36, 8019-8027.	1.7	9
14	Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10 years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. <i>Vaccine</i> , 2017, 35, 4034-4040.	1.7	12
15	Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. <i>Vaccine</i> , 2017, 35, 452-458.	1.7	15
16	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004926.	1.3	67
17	Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. <i>Journal of Experimental Medicine</i> , 2016, 213, 1061-1077.	4.2	45
18	Progress toward a Universal H5N1 Vaccine: A Recombinant Modified Vaccinia Virus Ankara-Expressing Trivalent Hemagglutinin Vaccine. <i>PLoS ONE</i> , 2014, 9, e107316.	1.1	17

#	ARTICLE	IF	CITATIONS
19	An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution. <i>Clinical Infectious Diseases</i> , 2014, 58, 1230-1240.	2.9	126
20	Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: A discussion of the adaptive licensure concept. <i>Tuberculosis</i> , 2014, 94, 178-182.	0.8	8
21	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. <i>Tuberculosis</i> , 2013, 93, 143-149.	0.8	35
22	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2013, 381, 1021-1028.	6.3	903
23	Demonstration of Immunologic Memory Using Serogroup C Meningococcal Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 92-97.	1.1	8
24	Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. <i>Pediatrics International</i> , 2008, 50, 295-299.	0.2	35
25	Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar [®] , [®]): Primary dosing series in healthy Chinese infants. <i>Vaccine</i> , 2008, 26, 2260-2269.	1.7	15
26	A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine. <i>Vaccine</i> , 2008, 26, 4602-4607.	1.7	14
27	Conjugate vaccines. <i>Expert Review of Vaccines</i> , 2003, 2, 633-648.	2.0	39
28	Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. <i>Vaccine</i> , 2001, 19, 2924-2931.	1.7	41
29	Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. <i>New England Journal of Medicine</i> , 2001, 344, 403-409.	13.9	1,366
30	Immunogenicity and Reactogenicity of Pneumococcal Conjugate Vaccines in Infants and Children. , 0, , 227-243.		0